Justin Stahl, MD
Neurology · Seattle, WANPI 1972691905
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $272 of the $330 with a category attached, or 82.4%. 6 manufacturers reported payments, led by Greenwich Biosciences, Inc. at 37.8% of the total. Reporting peaked in 2019 at $194 and has fallen 92.3% since, to $15 in 2025. That places this record below the midpoint for neurology clinicians in WA, where the typical reported total is $296.
Across 11 payments — averaging $30.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$125
- Biogen$66
- Amgen$51
- Novartis$47
- Bioventus LLC$26
- UCB, Inc.$15
Across 1 payment — averaging $23,465 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$23K
What the payments were for
- Food & beverage$27282%
- Education$5818%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 1 | $125 |
| Biogen | 2 | $66 |
| Amgen | 3 | $51 |
| Novartis | 3 | $47 |
| Bioventus LLC | 1 | $26 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$125
How this compares
$330 in reported general payments places this provider in the 50th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 12 | $766,020 |
| Emgality PenGalcanezumab-Gnlm | 53 | $40,540 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $39,448 |
| Ajovy SyringeFremanezumab-Vfrm | 21 | $22,234 |
| LyricaPregabalin | 12 | $18,735 |
| XcopriCenobamate | 13 | $14,044 |
| Carbamazepine ErCarbamazepine | 69 | $13,637 |
| Lamotrigine | 323 | $9,436 |
| Divalproex Sodium | 78 | $8,916 |
| Levetiracetam | 285 | $8,531 |
| Memantine Hcl | 203 | $7,953 |
| Lacosamide | 121 | $7,062 |
| Carbamazepine | 64 | $5,897 |
| Donepezil Hcl | 196 | $3,142 |
| Phenobarbital | 19 | $2,531 |
Paid to pharmacies, not to this prescriber.
Other neurology in Seattle
- Pavle RepovicSeattle$1.1M
- Nathaniel WatsonSeattle$486K
- Christyn EdmundsonSeattle$318K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
- Michael RosenbloomSeattle$179K
- Michael WeissSeattle$103K
- Sylvia LucasSeattle$90K
- Shuvro RoySeattle$46K
- Lucas McCarthySeattle$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.